NCT03829111View on ClinicalTrials.gov

CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 14, 2019

Primary Completion Date

December 13, 2023

Study Completion Date

December 13, 2023

Conditions
Advanced Renal Cell CarcinomaClear Cell Renal Cell CarcinomaMetastatic Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Unresectable Renal Cell Carcinoma
Interventions
DRUG

Clostridium butyricum CBM 588 Probiotic Strain

Given PO

BIOLOGICAL

Ipilimumab

Given IV

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT03829111 - CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer | Biotech Hunter | Biotech Hunter